

DAFTAR PUSTAKA

- Balzer, B.W.R., Loo, C., Lewis, C.R., Trahair, T.N., Anazodo, A.C. 2018. Adenocarcinoma of the Lung in Childhood and Adolescence: A Systematic Review. *J. Thorac. Oncol.*, 13(12):1832–1841.
- Barta, J.A., Powell, C.A., Wisnivesky, J.P. 2019. Global Epidemiology of Lung Cancer. *Ann. Glob. Heal.*, 85(1).
- Bethune, G., Bethune, D., Ridgway, N., Xu, Z. 2010. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. *J. Thorac. Dis.*, 2(1):48–51.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.*, 68(6):394–424.
- Byun, J., Schwartz, A.G., Lusk, C., Wenzlaff, A.S., de Andrade, M., Mandal, D., *et al.* 2018. Genome-wide association study of familial lung cancer. *Carcinogenesis*, 39(9):1135–1140.
- Cao, Y., Xu, H., Liao, M., Qu, Y., Xu, L., Zhu, D., *et al.* 2018. Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma. *Int. J. Clin. Oncol.*, 23(2):249–257.
- Chaudhry, S.R., Bordoni, B. 2024. *Anatomy, Thorax, Esophagus*. Treasure Island (FL): StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK482513/>.
- Chen, Y., Chen, J., Richard, K., Chen, P., Christiani, D.C. 2004. Lung adenocarcinoma and human papillomavirus infection. *Cancer*, 101(6):1428–1436.
- Deniffel, D., Sauter, A., Fingerle, A., Rummeny, E.J., Makowski, M.R., Pfeiffer, D. 2021. Improved differentiation between primary lung cancer and pulmonary metastasis by combining dual-energy CT–derived biomarkers with conventional CT attenuation. *Eur. Radiol.*, 31(2):1002–1010.
- Ettinger, D., Bharat, A., Wood, D., Aisner, D., Akerley, W., Bauman, J. 2019. *Non-small Cell Lung Cancer. JNCCN J. Natl. Compr. Cancer Network*, vol. 17.
- Fearon, K.C.H., Glass, D.J., Guttridge, D.C. 2012. Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways. *Cell Metab.*, 16(2):153–166.
- Gee, K., Yendamuri, S. 2024. Lung cancer in females—sex-based differences from males in epidemiology, biology, and outcomes: a narrative review. *Transl. Lung Cancer Res.*, 13(1):163–178.
- Guerra-Romero, L., Tauber, M.G., Fournier, M.A., Tureen, J.H. 1992. *Lactate and*

Glucose Concentrations in Brain Interstitial Fluid, Cerebrospinal Fluid, and Serum during Experimental Pneumococcal Meningitis Downloaded from. J. Infect. Dis. Available at: <http://jid.oxfordjournals.org/>.

- Han, X., Fan, J., Gu, J., Li, Y., Yang, M., Liu, T., Li, N., Zeng, W., Shi, H. 2020. CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas. *Cancer Imaging*, 20(1):51.
- Han, X., Fan, J., Li, Y., Cao, Y., Gu, J., Jia, X., *et al.* 2021. Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma. *Sci. Rep.*, 11(1):5679.
- Haroen, R.F., Herianto, D.S., Ferronika, P. 2023. *Hubungan Lokasi Tumor dengan Mutasi Epidermal Growth Factor Receptor pada kanker Paru Karsinoma Bukan Sel Kecil Jenis Adenokarsinoma*. Universitas Gajah Mada. Available at: <http://etd.repository.ugm.ac.id/>.
- Hasegawa, M., Sakai, F., Ishikawa, R., Kimura, F., Ishida, H., Kobayashi, K. 2016. CT Features of Epidermal Growth Factor Receptor–Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma. *J. Thorac. Oncol.*, 11(6):819–826.
- Hirsch, F.R., Varella-Garcia, M., Bunn, P.A., Di Maria, M. V., Veve, R., Bremnes, R.M., *et al.* 2003. Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis. *J. Clin. Oncol.*, 21(20):3798–3807.
- Howlader, N., Noone, A., Krapcho, M., Miller, D., Brest, A., Yu, M., *et al.* 2019. *SEER Cancer Statistics Review (CSR) 1975-2016*. Natl. Cancer Inst.
- Hsu, J.-S., Huang, M.-S., Chen, C.-Y., Liu, G.-C., Liu, T.-C., Chong, I.-W., *et al.* 2014. Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma. *J. Thorac. Imaging*, 29(6):357–363.
- Hutchinson, B.D., Shroff, G.S., Truong, M.T., Ko, J.P. 2019. Spectrum of Lung Adenocarcinoma. *Semin. Ultrasound, CT MRI*, 40(3):255–264.
- Jimeno, A., Hidalgo, M. 2006. Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. *Biochim. Biophys. Acta - Rev. Cancer*, 1766(2):217–229.
- Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1438/2023. 2023. *Pedoman nasional Pelayanan kedokteran Tatalaksana Kanker Paru*. Available at: www.kemkes.go.id.
- Liu, Y., Kim, J., Qu, F., Liu, S., Wang, H., Balagurunathan, Y., *et al.* 2016. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma. *Radiology*, 280(1):271–280.
- Mei, D., Luo, Y., Wang, Y., Gong, J. 2018. CT texture analysis of lung

- adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses. *Cancer Imaging*, 18(1):52.
- Mets, O., Smithuis, R. 2017. *TNM classification 8th edition*. Radiol. Assist. Available at: <https://radiologyassistant.nl/chest/lung-cancer/tnm-classification-8th-edition>.
- Morgensztern, D., Waqar, S., Subramanian, J., Trinkaus, K., Govindan, R. 2012. Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non-Small-Cell Lung Cancer. *J. Thorac. Oncol.*, 7(10):1485–1489.
- Mosesson, Y., Yarden, Y. 2004. Oncogenic growth factor receptors: implications for signal transduction therapy. *Semin. Cancer Biol.*, 14(4):262–270.
- Mourabiti, A.Y., Sqalli Houssaini, M., Benfares, A., El Bouardi, N., Alaoui Lamrani, M.Y., El Fatemi, H., Serraj, M., Amara, B., Qjidaa, H., Smahi, M., Maaroufi, M., Alami, B. 2023. Clinical and radiological features associated with EGFR mutation in non-small-cell lung cancer: a study of 149 cases. *Egypt. J. Radiol. Nucl. Med.*, 54(1):171.
- Myers, D.J., Wallen, J.M. 2024. *Lung Adenocarcinoma*. Treasure Island (FL): StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK519578/>.
- Nicholson, A.G., Tsao, M.S., Beasley, M.B., Borczuk, A.C., Brambilla, E., Cooper, W.A., *et al.* 2022. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. *J. Thorac. Oncol.*, 17(3):362–387.
- O’Leary, C., Gasper, H., Sahin, K.B., Tang, M., Kulasinghe, A., Adams, M.N., Richard, D.J., O’Byrne, K.J. 2020. Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). *Pharmaceuticals (Basel)*, 13(10).
- Perez-Johnston, R., Araujo-Filho, J.A., Connolly, J.G., Caso, R., Whiting, K., Tan, K.S., *et al.* 2022. CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes. *Radiology*, 303(3):664–672.
- Qiu, X., Yuan, H., Sima, B. 2019. Relationship between *EGFR* mutation and computed tomography characteristics of the lung in patients with lung adenocarcinoma. *Thorac. Cancer*, 10(2):170–174.
- Rizzo, S., Petrella, F., Buscarino, V., De Maria, F., Raimondi, S., Barberis, M., *et al.* 2016. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer. *Eur. Radiol.*, 26(1):32–42.
- RKBR Maret 2022. <https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/rkbr-maret-2022/>.
- Sacconi, B., Anzidei, M., Leonardi, A., Boni, F., Saba, L., Scipione, R., *et al.* 2017.

Analysis of CT features and quantitative texture analysis in patients with lung adenocarcinoma: a correlation with EGFR mutations and survival rates. *Clin. Radiol.*, 72(6):443–450.

Sakurada, A., Shepherd, F.A., Tsao, M.-S. 2006. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations. *Clin. Lung Cancer*, 7:S138–S144.

Sánchez-Ortega, M., Carrera, A.C., Garrido, A. 2021. Role of NRF2 in Lung Cancer. *Cells*, 10(8):1879.

Santos, M. koeningkam, Muley, T., Warth, A., de Paula, W.D., Lederlin, M., Schnabel, P.A., *et al.* 2014. Morphological computed tomography features of surgically resectable pulmonary squamous cell carcinomas: Impact on prognosis and comparison with adenocarcinomas. *Eur. J. Radiol.*, 83(7):1275–1281.

Sastroasmoro, S., Ismael, S. 2011. *Dasar-dasar Metodologi Penelitian Klinis*. 4th edn. Jakarta: Sagung Seto.

Stabile, L.P., Davis, A.L.G., Gubish, C.T., Hopkins, T.M., Luketich, J.D., Christie, N., Finkelstein, S., Siegfried, J.M. 2002. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. *Cancer Res.*, 62(7):2141–50.

Stabile, L.P., Dacic, S., Land, S.R., Lenzner, D.E., Dhir, R., Acquafondata, M., Landreneau, R.J., Grandis, J.R., Siegfried, J.M. 2011. Combined Analysis of Estrogen Receptor β -1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome. *Clin. Cancer Res.*, 17(1):154–164.

Sun, S., Schiller, J.H., Gazdar, A.F. 2007. Lung cancer in never smokers — a different disease. *Nat. Rev. Cancer*, 7(10):778–790.

Thandra, K.C., Barsouk, Adam, Saginala, K., Sukumar Aluru, J., Barsouk, Alexander. 2021. Epidemiology of lung cancer. *Współczesna Onkol.*, 25(1):45–52.

Verschakelen, J.A., De Wever, W. 2018. *Computed Tomography of the Lung*. Berlin, Heidelberg: Springer Berlin Heidelberg.

Wang, H., Guo, H., Wang, Z., Shan, B., Lin, J. 2019. The Diagnostic Value of Quantitative CT Analysis of Ground-Glass Volume Percentage in Differentiating Epidermal Growth Factor Receptor Mutation and Subtypes in Lung Adenocarcinoma. *Biomed Res. Int.*, 1–8.

Webb, W.R., Muller, N., Naidich, D. 2015. *High-Resolution CT Of The Lung*. 5th edn. Philadelphia: Wolters Kluwer Health.

Yamazaki, M., Yagi, T., Tominaga, M., Minato, K., Ishikawa, H. 2022. Role of

intratumoral and peritumoral CT radiomics for the prediction of EGFR gene mutation in primary lung cancer. *Br. J. Radiol.*, 95(1140).

Zhang, G., Zhao, Z., Cao, Y., Zhang, J., Li, S., Deng, L., *et al.* 2021. Relationship between epidermal growth factor receptor mutations and CT features in patients with lung adenocarcinoma. *Clin. Radiol.*, 76(6):473.e17-473.e24.

Zhou, J.Y., Zheng, J., Yu, Z.F., Xiao, W.B., Zhao, J., Sun, K., *et al.* 2015. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. *Eur. Radiol.*, 25(5):1257–1266.

Zhou, W., Christiani, D.C. 2011. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. *Chin. J. Cancer*, 30(5):287–292.

.